Galectin Therapeutics Inc. appointed Harold Shlevin as CEO and president, effective July 6.
Shlevin, who has been Galectin's COO since 2012, succeeds Peter Traber, who has tendered his resignation as president, CEO and chief medical officer.
Previously, Traber decided not to stand for re-election as a director at the annual stockholders meeting.
Norcross, Ga.-based Galectin Therapeutics is a clinical-stage biopharmaceutical company, which engages in the research and development of therapies for fibrotic disease and cancer.
